Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature?s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. Here we showcase our immunoSEQ Technology that provides a quantitative, end-to-end immunosequencing solution that helps you discover the breadth and depth of the adaptive immune system. From experimental design to publication ready data, this solution gives you the power to decipher the complexity of the adaptive immune system, providing fundamental insights into the body?s response to disease and therapy at the cellular level. We offer flexibility through a wide variety of sample types, including FFPE tissue, access to our assays through our Service lab or immunoSEQ hsTCRB Kit product, and dedicated support services to help optimize your experiments and navigate challenges. Our most recent product, immunoSEQ T-MAP COVID, provides tools for researchers to study the COVID-19 T-cell immune response, including detecting past SARS-CoV-2-specific immune response in research samples & the ability to track responses longitudinally. Explore our interactive and specially curated collection of high-value content including videos, webinars, blog posts, and more at www.seq-discovery.com immunoSEQ and immunoSEQ T-MAP COVID are For Research Use Only. Not for use in diagnostic procedures.